Coalition of advocates to vaccinate of Western European citizens aged 60 years and older

Aging Clinical and Experimental Research

Volumn 21, Issue 3, 2009, Pages 254-257

  Michel, Jean Pierre ^a   Chidiac, Christian ^b   Grubeck Loebenstein, Beatrix ^c   Johnson, Robert W ^d   Lambert, Paul Henri ^e   Maggi, Stefania ^f   Moulias, Robert ^g   Nicholson, Karl ^h   Werner, Hans ⁱ  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b CROIX ROUSSE HOSPITAL   (France)

^c Institute for Biomedical Aging Research   (Austria)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f CNR   (Italy)

^g HÔPITAL CHARLES FOIX   (France)

^h LEICESTER ROYAL INFIRMARY   (United Kingdom)

ⁱ Ev Krankenhaus Elisabethenstift   (Germany)

Author keywords

Healthy aging; Public health; Vaccine

Indexed keywords

DIPHTHERIA; HEALTH CARE PERSONNEL; HUMAN; INFECTION; INFLUENZA; MEDICAL INFORMATION; MEDICAL SOCIETY; PRACTICE GUIDELINE; REVIEW; STREPTOCOCCUS PNEUMONIA; TETANUS; VACCINATION; WESTERN EUROPE;

HERPES ZOSTER;

EID: 67651155887     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324911     Document Type: Review

References (19)

1. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23: 363-368
2. Kretsinger K, Broder KR, Cortese MM et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of TdaP among health-care personnel. MMWR Recomm Rep 2006; 55: 1-37.
3. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: 1-42.
4. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005; 165: 265-272
5. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7: 658-666
6. Nicholson KG. Socioeconomics of influenza and influenza vaccination in Europe. Pharmacoeconomics 1996; 9 (Suppl 3): 75-78
7. Patel MS, Davis MM. Could a federal program to promote influenza vaccination among elders be cost-effective? Prev Med 2006; 42: 240-246
8. Nichol KL, Nordin J, Mullooly J. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons. Vaccine 2006; 24: 1562-1568
9. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006; 31: 72-79
10. Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 2006; 24: 1035-1043
11. Prosser LA, O'Brien MA, Molinari NA et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics 2008; 26: 163-178
12. Evers SM, Ament AJ, Colombo GL, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007; 26: 531-540
13. Lee GM, Murphy TV, Lett S et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med 2007; 32: 186-193
14. Lee GM, Riffelmann M, Wirsing von Konig CH. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine 2008; 26: 3673-3679
15. Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis 2007; 45: 1527-1529
16. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44: 1280-1288
17. Lieu TA, Ortega-Sanchez I, Ray GT et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008; 26: 235-249
18. Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med 2008; 121: S28-35.
19. Kotchen TA. Why the slow diffusion of treatment guidelines into clinical practice? Arch Intern Med 2007; 167: 2394-2395